You have read all your free articles, to continue reading subscribe to read the rest of this content.
Oncopeptides has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), for OPD5 - a second drug candidate based on the Peptide Drug Conjugate platform (PDC). Oncopeptides plans to initiate clinical development of OPD5 with an open-label phase 1, dAlready a subscriber Login You…
AlzeCure Pharma has chosen a candidate drug (CD) and started the preclinical development phase with the company's preventive and disease-modifying candidate drug Alzstatin ACD680. ACD680 is being developed within AlzeCure's Alzstatin platform, with the aim of developing a preventive and disease-mAlready a subscriber Login You have read all your free…
AstraZeneca has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). âAlready a subscriber Login You have read all your free articles, to continue reading…
Swedish Orphan Biovitrum has announced that it intends to discontinue discovery/early research and partner R&D programmes outside its core focus areas. The new focus of the R&D organisation is expected to lead to annual savings of SEK 200–300 M on a full-year basis in 2020, which will iAlready a subscriber…
